The Effect of Milk Thistle Extract in the Treatment of Diabetic Nephropathy

Document Type : Original Article(s)

Authors

1 Asociate Professor, Deartment of Endocrinology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Medical Student, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Abstract

Background: Milk thistle has antioxidative effects and may improve renal performance. Our study investigated whether Milk thistle improve renal performance in patients with type II diabetes mellitus nephropathy.Methods: In this clinical trial study, after ethics committee approval, 65 Patients with type II diabetes mellitus were enrolled into a randomized simple sampling, prospective, double-blinded study. In the case group, was gave Milk thistle and control group was given placebo. We measured urine albumin/cratinine (A/C) ratio and eGFR before and after intervention. The gathered data were analyzed by t and paired-t tests. P < 0.05 was regarded as significant level.Finding: The groups were well matched for age, sex, and duration of diabetes. The mean age was 55.9 ± 6.5 and 57.7 ± 7.7 years in case and control groups, respectively. There was not any significant difference between A/C ratio in case and control groups after intervention (P > 0.05); but in case group, after intervention A/C ratio was worse than before it (P < 0.05).Conclusion: The results suggest that Milk thistle did not improve the renal performance in patients with type II diabetes mellitus. 

Keywords

References

  1. Breyer JA. Diabetic nephropathy in insulin-dependent patients. Am J Kidney Dis 1992; 20(6): 533-47.
  2. Hostetter TH. Diabetic nephropathy. In: Brenner BM, Rector FC, editors. Brenner and Rector's The Kidney. 8th ed. Philadelphia: Saunders; 2006. p. 1377-402.
  3. Milovanceva-Popovska M, Dzikova S. Progression of diabetic nephropathy: value of intrarenal resistive index (RI). Prilozi 2007; 28(1): 69-79.
  4. DiMario C, Dudek D, Piscione F. Diabetic nephrology in patients with diabetic melitus. Lancet 2008; 371: 559.
  5. Cannon CP, Murphy SA. Early diabetic nephrology in Type 2 diabetes. Am J Cardiol 2001; 88: 831.
  6. Drobatz KJ, Hess RS. Outcome of patients with diabetic nephropathy: (1993-2003). J Vet Intern Med 2006; 20(3): 547-55.
  7. Kayima JK, Omonge EO, Oyoo GO. Diabetic nephropathy: risk factors, mechanisms and management strategies in sub-Saharan Africa: a review. East Afr Med J 2006; 82(12 Suppl): S197-203.
  8. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414(6865): 782-7.
  9. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21(9): 1414-31.
  10. Medscap today - Diabetes care; joryel Gross MD; Mirelajde Azevedo MD Sandra P Silveriro, MD; Luis Henrique canani, MD; Marialuiza Caramori, MD; themis zelmanovitz, MD, Authors & Disclosures Published, 1, 24, 2005.
  11. Ismail N, Becker B, Strzelczyk P, Ritz E. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 1999; 55(1): 1-28.
  12. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414(6865): 813-20.
  13. Nakhjavani M. Oxidative stress and diabetes mellitus.Proceeding of the 2nd Iranian congress of Endocrine & Metabolism; 2009.April 22-24; Isfan, Iran.
  14. Ha H, Lee HB. Oxidative stress in diabetic nephropathy: Basic and clinical information. Current Diabetes Reports 2001; 1(3): 282-7.
  15. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci U S A 1993; 90(17): 7915-22.
  16. Soto CP, Perez BL, Favari LP, Reyes JL. Prevention of alloxan-induced diabetes mellitus in the rat by silymarin. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998; 119(2): 125-9.
  17. Manna SK, Mukhopadhyay A, Van NT, Aggarwal BB. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J Immunol 1999; 163(12): 6800-9.
  18. Gaedeke J, Fels LM, Bokemeyer C, Mengs U, Stolte H, Lentzen H. Cisplatin nephrotoxicity and protection by silibinin. Nephrol Dial Transplant 1996; 11(1): 55-62.
  19. Rastogi R, Srivastava AK, Rastogi AK. Long term effect of aflatoxin B(1) on lipid peroxidation in rat liver and kidney: effect of picroliv and silymarin. Phytother Res 2001; 15(4): 307-10.
  20. He Q, Kim J, Sharma RP. Silymarin protects against liver damage in BALB/c mice exposed to fumonisin B1 despite increasing accumulation of free sphingoid bases. Toxicol Sci 2004; 80(2): 335-42.
  21. Naderi MM, Oliazadeh N, Jamshidi AA, Ahmadi Ashtiani HR, Jafarzadeh M, Taheri Boroujerdi M, et al. A key to thousand unlock: Comprehensive review of herbal medicine (Silymarin) and Introducing of Silybum marianum. Tehran: Noavar; 2007.
  22. Sweetman SC. Martindale: The Complete Drug Reference. 36th ed. London: Pharmaceutical Press; 2009.
  23. Albrecht M, Frerick H, Kuhn U. Therapy of toxic liver pathologies with Legalon. Z Klin Med 1992; 47(87): 92.
  24. Abascal K, Yarnell E. The many faces of silybum marianum (Milk thistle) Part 2-clinical uses, safty and types of proparatios. Alternative and ComplementaryTherapies 2003; 251-6.
  25. Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 2000; 52(4): 673-751.
Journal of Isfahan Medical School
Volume 28, Issue 124 - Serial Number 124
November and December 2011
Pages 1997-2010

Files

History

  • Receive Date: 04 April 2011
  • Revise Date: 27 April 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics